Neuromyelitis optica spectrum disorder medical therapy

Neuromyelitis optica spectrum disorder Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Neuromyelitis optica spectrum disorder from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Interventions
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Neuromyelitis optica spectrum disorder medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Neuromyelitis optica spectrum disorder medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Neuromyelitis optica spectrum disorder medical therapy
CDC on Neuromyelitis optica spectrum disorder medical therapy
Neuromyelitis optica spectrum disorder medical therapy in the news
Blogs on Neuromyelitis optica spectrum disorder medical therapy
Directions to Hospitals Treating Neuromyelitis optica spectrum disorder
Risk calculators and risk factors for Neuromyelitis optica spectrum disorder medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes

Overview

The mainstay of treatment for neuromyelitis optica spectrum disorder (NMOSD) is prompt treatment of acute attacks and long-term immunotherapy to prevent relapses. Treatment selection depends on aquaporin-4 immunoglobulin G (AQP4-IgG) antibody status, attack severity, comorbidities, reproductive plans, and treatment availability. The 2026 Middle East and North Africa Committee for Treatment and Research in Multiple Sclerosis (MENACTRIMS) guidelines support early attack treatment and individualized preventive immunotherapy.

Medical Therapy

Treatment of Acute Attacks

Neuromyelitis optica spectrum disorder attacks require urgent glucocorticoid treatment and early apheresis when indicated.

The adult glucocorticoid regimen below follows the Neuromyelitis Optica Study Group (NEMOS) recommendations.

• Glucocorticoids: A usual adult regimen is methylprednisolone 1,000 mg intravenously (IV) daily for 3–5 days.
• Plasma exchange: Initiate early for severe attacks or inadequate early recovery with glucocorticoids. Severe attacks may require concurrent glucocorticoids and plasma exchange.
• Immunoadsorption: An alternative apheresis treatment where available.
• After the attack: Individualize an oral glucocorticoid taper, including bridging treatment while preventive immunotherapy becomes effective.

Long-Term Relapse Prevention

Neuromyelitis optica spectrum disorder associated with AQP4-IgG should be offered preventive immunotherapy after the first attack.

Treatment selection should consider efficacy, safety, attack severity, comorbidities, administration preferences, and access. Patients who remain relapse-free and tolerate their current treatment do not automatically need to switch to a newer drug.

Approved Targeted Therapies

Neuromyelitis optica spectrum disorder with positive AQP4-IgG can be treated with the targeted agents below. The listed regimens are adult regimens from the cited United States prescribing information; approvals and age eligibility vary by country.

• Eculizumab: Inhibits complement component 5 (C5). Administer 900 mg IV weekly for four doses, then 1,200 mg one week later, followed by 1,200 mg every two weeks.
• Ravulizumab: A long-acting C5 inhibitor. For adults weighing at least 40 kg, use a weight-based IV loading dose and weight-based maintenance dosing beginning two weeks later, then every eight weeks.
• Inebilizumab: Depletes B cells expressing cluster of differentiation 19 (CD19). Administer 300 mg IV initially and again two weeks later; subsequent 300 mg infusions are given every six months, starting six months after the first infusion.
• Satralizumab: Blocks the interleukin-6 (IL-6) receptor. Administer 120 mg subcutaneously at weeks 0, 2, and 4, followed by 120 mg every four weeks.

Other Immunotherapies

Neuromyelitis optica spectrum disorder prevention may also use rituximab, tocilizumab, or conventional immunosuppressants according to availability and patient factors.

• Rituximab: Depletes B cells expressing cluster of differentiation 20 (CD20). It is an established option whose regulatory status varies by jurisdiction.
• Tocilizumab: An IL-6 receptor blocker considered in selected patients, including treatment-refractory disease; its use for NMOSD is generally off-label.
• Azathioprine or mycophenolate mofetil: Oral immunosuppressive alternatives, particularly where biologic therapies are inaccessible.

AQP4-IgG-Negative Disease

Neuromyelitis optica spectrum disorder with negative AQP4-IgG requires careful exclusion of alternatives, including myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).

For patients negative for both AQP4-IgG and myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG), the 2026 Malaysian consensus supports considering maintenance immunosuppression for relapsing or severe disease at high risk of further attacks or disability. Options include rituximab, azathioprine, or mycophenolate mofetil; evidence remains limited.

Treatment Safety and Monitoring

Neuromyelitis optica spectrum disorder immunotherapy requires drug-specific infection screening, vaccination planning, laboratory monitoring, and assessment for adverse effects.

• Complement inhibitors: Give meningococcal vaccination covering serogroups A, C, W, Y, and B at least two weeks before eculizumab or ravulizumab when feasible. If treatment is urgent and vaccination is incomplete, provide antibacterial prophylaxis and vaccinate as soon as possible. Serious meningococcal infection can occur despite vaccination.
• Inebilizumab: Screen for hepatitis B and tuberculosis and measure serum immunoglobulins before treatment. Use infusion premedication and monitor for infusion reactions, infection, and reduced immunoglobulin levels.
• Satralizumab: Screen for hepatitis B and tuberculosis, assess liver tests, and monitor liver enzymes and neutrophil counts. Delay administration during active infection.
• Apheresis interactions: Plasma exchange can remove complement inhibitors; follow the relevant prescribing information for supplemental dosing.

Breakthrough severe attacks or significant adverse effects warrant reassessment of treatment efficacy, exposure, and the need to switch therapy.

Pregnancy and Breastfeeding

Neuromyelitis optica spectrum disorder pregnancy planning requires review of preventive therapy before conception and a plan for postpartum relapse prevention. Mycophenolate mofetil must be avoided during pregnancy and breastfeeding.

Symptomatic Medical Therapy

Neuromyelitis optica spectrum disorder may require treatment of persistent symptoms alongside relapse prevention. Much of the evidence for symptomatic medications is extrapolated from multiple sclerosis or spinal cord injury.

• Neuropathic pain: Options include gabapentin, pregabalin, or duloxetine.
• Spasticity: Oral baclofen or tizanidine may help; combine medication with stretching and physiotherapy.
• Painful tonic spasms: Carbamazepine or oxcarbazepine may be effective.
• Other needs: Individualize management of bladder, bowel, mood, sleep, and rehabilitation needs.

Drugs to Avoid

Neuromyelitis optica spectrum disorder can worsen with interferon beta, natalizumab, fingolimod, alemtuzumab, or dimethyl fumarate. Glatiramer acetate is ineffective; mitoxantrone is discouraged because of toxicity.